CMMI director Adam Boehler appointed to advise on value-based care innovations

Adam Boehler, the director of the Center for Medicare & Medicaid Innovation (CMMI), has been appointed to serve as a senior adviser to HHS’s Value-Based Transformation and Innovation.

The value-based care initiative is one of four key department priorities identified by HHS Secretary Alex Azar. Boehler was appointed to CMMI earlier this year. He previously served as CEO of healthcare startup Landmark Health, which he founded in 2013 and provides in-home care to chronically ill patients.

“Adam is the kind of results-oriented, transformational leader we need to deliver on what President Trump has promised the American people: better healthcare at a lower cost,” Azar said in a statement. “At CMMI, he has already demonstrated an ambition for bold change, and will now be able to bring his deep experience with private sector innovation to help HHS execute on the long-talked-about goal of transforming our healthcare system into one that pays for value.”

The agency has appointed three other senior advisors to lead the priorities. Jim Parker was named senior advisor for Health Reform and director of the Office of Health Reform, Dan Best was appointed senior advisor for Drug Pricing Reform and Brett Giroir, MD, was named senior advisor for Opioid and Mental Health Policy.

The four advisors will aim to advance the four initiatives of the agency.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.